Search - tctmd.com

Displaying 1 - 20 of 28

Sort: Relevancy | Date

Presentation THT 2025

What Lessons Can We Learn from DanGer in the Management of HF-CS

Presenter: Jacob Abraham

February 11, 2025

Presentation THT 2025

Discuss Escalation Strategies for Patients in HF-CS

Presenter: Jane Wilcox

February 11, 2025

Presentation THT 2025

Explain the Importance of Timely Identification of Patients in Heart Failure-Cardiogenic Shock (HF-CS)

Presenter: Navin Kapur

February 11, 2025

Presentation THT 2024

Innovations in Management of ECMO-Supported Patients

Presenter: E Wilson Grandin

March 05, 2024

Presentation THT 2024

Innovations for RV Support in Shock

Presenter: Jaime Hernandez Montfort

March 05, 2024

Presentation THT 2024

Cardiogenic Shock: The Urgent Need for Innovation in Devices and Technologies for Shock

Presenter: Navin K. Kapur

March 05, 2024

Presentation THT 2024

Durrable LVADs: Innovations in Programming and Management Required to Advance the Field

Presenter: Melana Yuzefpolskaya

March 04, 2024

Presentation THT 2024

Durable LVADs: Pump Innovations Required to Advance the Field

Presenter: Francis D. Pagani

March 04, 2024

Presentation THT 2024

Participant-Centric, Digital, and Decentralized: What Are the Innovations We Need in How We Do Research?

Presenter: Harlan Krumholz

March 04, 2024

News Conference News THT 2023

Meta-analysis Hints at Survival Benefit With LAP Monitoring in HFrEF

Shelley Wood

March 22, 2023

Presentation THT 2023

Are All Incentives Altruistic?: The Importance of Measurement

Presenter: Marvin Konstam

March 20, 2023

Presentation THT 2023

Medicare Coverage and Postmarket Evidence on Emerging Cardiovascular Devices

Presenter: Beena Bhuiyan Khan

March 20, 2023

Presentation THT 2023

Who Bears the Cost of Innovation?

Presenter: Philip Adamson

March 20, 2023

Presentation THT 2023

A Payors Perspective: Innovative Models to Reduce Cost

Presenter: Lonny Reisman

March 20, 2023

Presentation THT 2023

The Projected Burden of Heart Failure

Presenter: Joseph Rogers

March 20, 2023

Presentation THT 2023

Assessing the Residual Risk: What Gaps Should New Technologies Fill?

Presenter: Javed Butler

March 20, 2023

Presentation THT 2023

The AI Revolution and How It Is Impacting Health Care Delivery in Heart Failure

Presenter: Nir Uriel

March 20, 2023

Presentation THT 2023

Recent Advances in the Medical Treatment of Patients With Decompensated Heart Failure

Presenter: Alexandre Mebazaa

March 20, 2023

Presentation THT 2023

Contemporary Implementation of Guideline-Directed Therapy for Heart Failure

Presenter: Gad Cotter

March 20, 2023

Presentation THT 2023

SGLT2 Inhibitors Have a Unique Mechanism That Accounts for Their Comprehensive Benefits

Presenter: Milton Packer

March 20, 2023

Advertisement

What Lessons Can We Learn from DanGer in the Management of HF-CS

Discuss Escalation Strategies for Patients in HF-CS

Explain the Importance of Timely Identification of Patients in Heart Failure-Cardiogenic Shock (HF-CS)

Innovations in Management of ECMO-Supported Patients

Innovations for RV Support in Shock

Cardiogenic Shock: The Urgent Need for Innovation in Devices and Technologies for Shock

Durrable LVADs: Innovations in Programming and Management Required to Advance the Field

Durable LVADs: Pump Innovations Required to Advance the Field

Participant-Centric, Digital, and Decentralized: What Are the Innovations We Need in How We Do Research?

Meta-analysis Hints at Survival Benefit With LAP Monitoring in HFrEF

Are All Incentives Altruistic?: The Importance of Measurement

Medicare Coverage and Postmarket Evidence on Emerging Cardiovascular Devices

Who Bears the Cost of Innovation?

A Payors Perspective: Innovative Models to Reduce Cost

The Projected Burden of Heart Failure

Assessing the Residual Risk: What Gaps Should New Technologies Fill?

The AI Revolution and How It Is Impacting Health Care Delivery in Heart Failure

Recent Advances in the Medical Treatment of Patients With Decompensated Heart Failure

Contemporary Implementation of Guideline-Directed Therapy for Heart Failure

SGLT2 Inhibitors Have a Unique Mechanism That Accounts for Their Comprehensive Benefits

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content